237 related articles for article (PubMed ID: 35938660)
1. Neuromyelitis Optica Spectrum Disorders.
Costello F
Continuum (Minneap Minn); 2022 Aug; 28(4):1131-1170. PubMed ID: 35938660
[TBL] [Abstract][Full Text] [Related]
2. Contemporary management challenges in seropositive NMOSD.
Costello F; Burton JM
J Neurol; 2022 Oct; 269(10):5674-5681. PubMed ID: 35816205
[TBL] [Abstract][Full Text] [Related]
3. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
6. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
[TBL] [Abstract][Full Text] [Related]
7. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
9. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
11. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
[TBL] [Abstract][Full Text] [Related]
12. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
13. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
[TBL] [Abstract][Full Text] [Related]
14. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
15. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
[TBL] [Abstract][Full Text] [Related]
16. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents.
Paolilo RB; Paz JAD; Apóstolos-Pereira SL; Rimkus CM; Callegaro D; Sato DK
Arq Neuropsiquiatr; 2023 Feb; 81(2):201-211. PubMed ID: 36948203
[TBL] [Abstract][Full Text] [Related]
18. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
Anderson M; Levy M
J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]